BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 19657370)

  • 1. Retroviral vector integration in post-transplant hematopoiesis in mice conditioned with either submyeloablative or ablative irradiation.
    Sadat MA; Dirscherl S; Sastry L; Dantzer J; Pech N; Griffin S; Hawkins T; Zhao Y; Barese CN; Cross S; Orazi A; An C; Goebel WS; Yoder MC; Li X; Grez M; Cornetta K; Mooney SD; Dinauer MC
    Gene Ther; 2009 Dec; 16(12):1452-64. PubMed ID: 19657370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term correction of phagocyte NADPH oxidase activity by retroviral-mediated gene transfer in murine X-linked chronic granulomatous disease.
    Dinauer MC; Li LL; Björgvinsdóttir H; Ding C; Pech N
    Blood; 1999 Aug; 94(3):914-22. PubMed ID: 10419882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term high-level reconstitution of NADPH oxidase activity in murine X-linked chronic granulomatous disease using a bicistronic vector expressing gp91phox and a Delta LNGFR cell surface marker.
    Sadat MA; Pech N; Saulnier S; Leroy BA; Hossle JP; Grez M; Dinauer MC
    Hum Gene Ther; 2003 May; 14(7):651-66. PubMed ID: 12804147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retrovirus gene therapy for X-linked chronic granulomatous disease can achieve stable long-term correction of oxidase activity in peripheral blood neutrophils.
    Kang EM; Choi U; Theobald N; Linton G; Long Priel DA; Kuhns D; Malech HL
    Blood; 2010 Jan; 115(4):783-91. PubMed ID: 19965657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Third-generation, self-inactivating gp91(phox) lentivector corrects the oxidase defect in NOD/SCID mouse-repopulating peripheral blood-mobilized CD34+ cells from patients with X-linked chronic granulomatous disease.
    Roesler J; Brenner S; Bukovsky AA; Whiting-Theobald N; Dull T; Kelly M; Civin CI; Malech HL
    Blood; 2002 Dec; 100(13):4381-90. PubMed ID: 12393624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retroviral gene therapy for X-linked chronic granulomatous disease: results from phase I/II trial.
    Kang HJ; Bartholomae CC; Paruzynski A; Arens A; Kim S; Yu SS; Hong Y; Joo CW; Yoon NK; Rhim JW; Kim JG; Von Kalle C; Schmidt M; Kim S; Ahn HS
    Mol Ther; 2011 Nov; 19(11):2092-101. PubMed ID: 21878903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stable long-term gene correction with low-dose radiation conditioning in murine X-linked chronic granulomatous disease.
    Goebel WS; Pech NK; Dinauer MC
    Blood Cells Mol Dis; 2004; 33(3):365-71. PubMed ID: 15528159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concentrated RD114-pseudotyped MFGS-gp91phox vector achieves high levels of functional correction of the chronic granulomatous disease oxidase defect in NOD/SCID/beta -microglobulin-/- repopulating mobilized human peripheral blood CD34+ cells.
    Brenner S; Whiting-Theobald NL; Linton GF; Holmes KL; Anderson-Cohen M; Kelly PF; Vanin EF; Pilon AM; Bodine DM; Horwitz ME; Malech HL
    Blood; 2003 Oct; 102(8):2789-97. PubMed ID: 12829597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-level reconstitution of respiratory burst activity in a human X-linked chronic granulomatous disease (X-CGD) cell line and correction of murine X-CGD bone marrow cells by retroviral-mediated gene transfer of human gp91phox.
    Ding C; Kume A; Björgvinsdóttir H; Hawley RG; Pech N; Dinauer MC
    Blood; 1996 Sep; 88(5):1834-40. PubMed ID: 8781441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biochemical correction of X-CGD by a novel chimeric promoter regulating high levels of transgene expression in myeloid cells.
    Santilli G; Almarza E; Brendel C; Choi U; Beilin C; Blundell MP; Haria S; Parsley KL; Kinnon C; Malech HL; Bueren JA; Grez M; Thrasher AJ
    Mol Ther; 2011 Jan; 19(1):122-32. PubMed ID: 20978475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retroviral-mediated gene transfer of gp91phox into bone marrow cells rescues defect in host defense against Aspergillus fumigatus in murine X-linked chronic granulomatous disease.
    Björgvinsdóttir H; Ding C; Pech N; Gifford MA; Li LL; Dinauer MC
    Blood; 1997 Jan; 89(1):41-8. PubMed ID: 8978275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simian immunodeficiency virus lentivector corrects human X-linked chronic granulomatous disease in the NOD/SCID mouse xenograft.
    Naumann N; De Ravin SS; Choi U; Moayeri M; Whiting-Theobald N; Linton GF; Ikeda Y; Malech HL
    Gene Ther; 2007 Nov; 14(21):1513-24. PubMed ID: 17728796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug-selected co-expression of P-glycoprotein and gp91 in vivo from an MDR1-bicistronic retrovirus vector Ha-MDR-IRES-gp91.
    Sugimoto Y; Tsukahara S; Sato S; Suzuki M; Nunoi H; Malech HL; Gottesman MM; Tsuruo T
    J Gene Med; 2003 May; 5(5):366-76. PubMed ID: 12731085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alpharetroviral vector-mediated gene therapy for X-CGD: functional correction and lack of aberrant splicing.
    Kaufmann KB; Brendel C; Suerth JD; Mueller-Kuller U; Chen-Wichmann L; Schwäble J; Pahujani S; Kunkel H; Schambach A; Baum C; Grez M
    Mol Ther; 2013 Mar; 21(3):648-61. PubMed ID: 23207695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correction of respiratory burst activity in X-linked chronic granulomatous cells to therapeutically relevant levels after gene transfer into bone marrow CD34+ cells.
    Becker S; Wasser S; Hauses M; Hossle JP; Ott MG; Dinauer MC; Ganser A; Hoelzer D; Seger R; Grez M
    Hum Gene Ther; 1998 Jul; 9(11):1561-70. PubMed ID: 9694155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene therapy of chronic granulomatous disease.
    Grez M; Becker S; Saulnier S; Knöss H; Ott MG; Maurer A; Dinauer MC; Hoelzer D; Seger R; Hossle JP
    Bone Marrow Transplant; 2000 May; 25 Suppl 2():S99-104. PubMed ID: 10933200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional reconstitution of oxidase activity in X-linked chronic granulomatous disease by retrovirus-mediated gene transfer.
    Zentilin L; Tafuro S; Grassi G; Garcia R; Ventura A; Baralle F; Falaschi A; Giacca M
    Exp Cell Res; 1996 Jun; 225(2):257-67. PubMed ID: 8660913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A murine model of antimetabolite-based, submyeloablative conditioning for bone marrow transplantation: biologic insights and potential applications.
    Goebel WS; Pech NK; Meyers JL; Srour EF; Yoder MC; Dinauer MC
    Exp Hematol; 2004 Dec; 32(12):1255-64. PubMed ID: 15588950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retroviral-mediated gene transfer and nonmyeloablative conditioning: studies in a murine X-linked chronic granulomatous disease model.
    Goebel WS; Dinauer MC
    J Pediatr Hematol Oncol; 2002 Dec; 24(9):787-90. PubMed ID: 12468930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Donor chimerism and stem cell function in a murine congenic transplantation model after low-dose radiation conditioning: effects of a retroviral-mediated gene transfer protocol and implications for gene therapy.
    Goebel WS; Yoder MC; Pech NK; Dinauer MC
    Exp Hematol; 2002 Nov; 30(11):1324-32. PubMed ID: 12423686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.